Isolagen And FDA Reach Agreement On Phase III Protocol Design

Isolagen, Inc. (Amex: ILE) announced today that the Company has reached an agreement with the Food and Drug Administration (FDA) on the design of its Phase III pivotal study protocol for the use of Isolagen(TM) Therapy for the treatment of wrinkles.

The protocol was submitted to the FDA under the agency's Special Protocol Assessment (SPA) regulations. The SPA process allows for FDA evaluation of a clinical trial protocol that will form the basis of an efficacy claim for a marketing application, and provides a binding agreement that the study design -- including patient numbers, clinical endpoints, and analyses -- are acceptable to the FDA.

"We are very pleased that the FDA has completed the SPA review process and agreed with our protocol design," said Nicholas L. Teti, Isolagen Chairman and Chief Executive Officer. "We are eager to begin the Isolagen Therapy registration trials for the treatment of wrinkles and plan to begin enrolling patients as soon as possible. This is a key milestone for the Company. I applaud our clinical and regulatory team for this achievement."

The randomized, double-blind, pivotal Phase III trials will evaluate the efficacy and safety of Isolagen(TM) Therapy (IT) against placebo for the treatment of nasolabial skin fold wrinkles. Each trial will include 200 patients.

ABOUT ISOLAGEN, INC.

Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: www.isolagen.com.

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward- looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. There is no assurance that the study that is the focus of the SPA disclosed above will be successful, that Isolagen(TM) Therapy will ever gain approval to be marketed in the United States or if approved will be marketed in the United States, or that if marketed that it will achieve its objectives or that the Company will achieve profitable operations. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, as well as other public filings with the SEC since such date.

Isolagen, Inc
www.isolagen.com

Knowledge is Power. Information is How You Get It!

Anti-Aging, Wrinkle Treatments
FREE SHIPPING AND FREE SAMPLES WITH EVERY ORDER!! Strivectin, ddf Prevage, Kinerase, M.D. Forte, Skin Medica, TNS Recovery Complex...
HYLEXIN
Specifically developed to address the underlying cause of serious dark under-eye circles

Do you want to advertise on this site? Click for details...